SciSparc Ltd. - Ordinary Shares (SPRC)

0.1955
-0.1045 (-34.83%)
NASDAQ · Last Trade: Nov 21st, 4:49 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.3000
Open0.2570
Bid0.1785
Ask0.1831
Day's Range0.1668 - 0.2623
52 Week Range0.1668 - 29.88
Volume4,661,238
Market Cap28.38M
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume6,484,794

Chart

About SciSparc Ltd. - Ordinary Shares (SPRC)

SciSparc Ltd. is a biotechnology company focused on the development and commercialization of innovative treatments for various medical conditions, particularly those related to the central nervous system. The company is engaged in advancing therapies that aim to address significant unmet needs, utilizing its proprietary platform to explore and enhance the effectiveness of cannabinoid-based treatments. Through its research and development efforts, SciSparc aims to create novel solutions that enhance patient outcomes and improve quality of life in underserved therapeutic areas. Read More

News & Press Releases

Today's Top Stock Movers: MSS Surges 97.0%, VWAV Plunges 71.02%chartmill.com
Via Chartmill · November 20, 2026
Top Movers in Today's US Session: SLDPW and MSS Lead Gainers; VWAV and BBA.W Lead Loserschartmill.com
Via Chartmill · November 20, 2026
US Stock Gap Movers for Nov. 20, 2026chartmill.com
Via Chartmill · November 20, 2026
Premarket Movers on Nov. 20, 2026: Gainers and Loserschartmill.com
Via Chartmill · November 20, 2026
Most Active Stocks on Nov. 19: VIVS, CHSN and NVDA Top Volumechartmill.com
Via Chartmill · November 19, 2026
Premarket Small-Cap Movers: Nov. 19, 2026 Gainers and Loserschartmill.com
Via Chartmill · November 19, 2026
After-Hours Small-Cap Movers: Gainers and Losers After Today's US Closechartmill.com
Via Chartmill · November 17, 2026
SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB
Appointment of the former Head of Israel’s National Security Council and Former Acting National Security Advisor to Prime Minister Benjamin Netanyahu marks another step in laying the scientific and strategic foundation for SciSparc’s planned entry into the Agentic AI sector
By SciSparc Ltd · Via GlobeNewswire · November 16, 2026
Top U.S. Gainers and Losers for Oct. 27, 2026 Sessionchartmill.com
Via Chartmill · October 27, 2026
Top Market Movers: US Gainers and Losers for October 27, 2026chartmill.com
Via Chartmill · October 27, 2026
Gap-Up and Gap-Down Stocks in Today's Sessionchartmill.com
Via Chartmill · October 27, 2026
Premarket Movers: Gainers and Losers Ahead of Today's US Openchartmill.com
Via Chartmill · October 27, 2026
After-Hours Movers: SNTI, BRAI, CLS Rise; SPRC, DVLT Fallchartmill.com
Via Chartmill · October 26, 2026
US Session Top Percentage Movers: Gainers and Losers Among Small-Cap Stockschartmill.com
Via Chartmill · October 26, 2026
Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Sessionchartmill.com
Via Chartmill · October 26, 2026
Premarket Movers: Gainers and Losers Ahead of Today's US Sessionchartmill.com
Via Chartmill · October 26, 2026
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.
By SciSparc Ltd · Via GlobeNewswire · October 22, 2026
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.
By SciSparc Ltd · Via GlobeNewswire · October 19, 2026
Thursday's after hours session: top gainers and loserschartmill.com
Via Chartmill · October 15, 2026
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.
By SciSparc Ltd · Via GlobeNewswire · October 15, 2026
SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s  majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.
By SciSparc Ltd · Via GlobeNewswire · October 7, 2026
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders
By SciSparc Ltd · Via GlobeNewswire · September 23, 2026
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult Tourette Syndrome
Via TheNewswire.com · September 2, 2026
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult Tourette Syndrome
By SciSparc Ltd · Via GlobeNewswire · September 2, 2026
Wondering what's happening in today's after-hours session?chartmill.com
Via Chartmill · August 31, 2026